Neville White’s Post

Hot off the press! Treatment of Post-operative Chylothorax: The Role of Intranodal Lymphangiography and Thoracic Duct Disruption. We present a clinical case of post-operative high-output (> 1 L/ day) chylothorax that resolved after intranodal lymphangiography and thoracic duct disruption, highlighting the therapeutic role of these techniques. Pedro Costa Herculano Moreira Teresa Dionísio Pedro Sousa https://lnkd.in/dBqiCX_p

Practice guidelines and quality metrics are based on compelling science. AtriCure’s LeAAPS™ Trial is a pivotal initiative intended to evaluate the safety and effectiveness of surgical LAA exclusion to prevent stroke in patients with an elevated risk, but no history of Afib. Learn more about this groundbreaking trial: https://okt.to/9c304M #ClinicalTrial #leaaps #LAAE #stroke

In the 📕#RedJournal: Rates of Recurrent Intestinal Metaplasia and Dysplasia After Successful Endoscopic Therapy of Barrett's Neoplasia by Endoscopic Mucosal Resection vs Endoscopic Submucosal Dissection and Ablation: A Large North American Multicenter Cohort Vantanasiri, et al. 👉 bit.ly/3XByZHm

Do you want to take a chance that your patient may lose MR eligibility due to impedance conditions? A recent study showed that is what happened with 43% of non-Medtronic SureScan™ SCS patients† at five years post-implant.(1) With Medtronic SureScan™ systems, 100% of SCS patients have MR access regardless of impedance.‡ Stop by our booth or join us for our lunch symposium where industry leaders, Drs. Chris Beuer, Krishnan Chakravarthy, Samir Sheth, Ricardo Vallejo, and Thomas White, will review the broad comprehensive pain product portfolio, unmatched MRI access§, and discuss clinical outcomes. #MDTPainInterventions #SCS #NANS2024 #NANS24 #MRI #PatientsFirst †Abbott, Boston Scientific, and Nevro ‡ Assuming all other conditions are met § Under specific conditions. Refer to product labeling for full list of conditions. (1) Mullins CF, Harris S, Pang D. A retrospective review of elevated lead impedances in impedance-dependent magnetic resonance-conditional spinal cord stimulation devices. Pain Pract. 2023;00:1–8

Exciting news from Biosplice! We're participating in the World Congress of Osteoarthritis (WCO) 2024, taking place from April 11th to 15th in London, UK. At this year's conference, we're excited to present our latest research findings: 🔹 Oral Presentation: "Radiographic and Pain Outcomes from a Phase 3 Extension Study (OA-07) Evaluating the Safety and Efficacy of Repeat Lorecivivint Injections Over 3 Years in Subjects with Severe Knee Osteoarthritis." 🔹 Oral Poster Presentation P674: "Treatment with Lorecivivint Leads to Improved Long-Term Patient Acceptable Symptom State (PASS) Compared to Placebo: Data from Phase 3 Extension Trial." These presentations highlight our ongoing commitment to advancing the treatment landscape for osteoarthritis and working to improve patient outcomes. #WCO2024 #Biosplice #London

Advanced Interventional Procedures for Knee Osteoarthritis: What Is the Current Evidence? https://bit.ly/4ecIwuP #OA #KneeOsteoarthritis #Osteoarthritis

✅ Key takeaways: 🟣 Transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) are associated with comparable adverse outcome rates after 10 years, according to new data published in European Heart Journal.[1] 🔵 There were, however, certain differences between the two treatment options that cardiologists should remember when recommending treatment for patients with severe aortic stenosis (AS). 🟢 “The general recommendation for the use of surgical bioprosthetic aortic valves as opposed to mechanical valves is age older than 65 years, but as TAVR offers a less invasive treatment, an increasing number of younger patients are now treated with transcatheter heart valves (THVs),” wrote first author Hans Gustav Hørsted Thyregod, MD, PhD, with Copenhagen University Hospital in Denmark, and colleagues. 🟡 “In the United States, about half of the patients younger than 65 years treated for isolated AS undergo TAVR. Due to the longer life expectancy of these patients, evidence on long-term durability of THV vs. surgical bioprostheses is needed.”

On September 16, 1977, Dr. Andreas Gruentzig performed the first percutaneous transluminal coronary angioplasty (PTCA). Since then, #angioplasty has evolved with advancements and today, it’s a cornerstone of #interventionalcardiology. Currently, approximately 1.5 to 2 million angioplasties are performed annually worldwide. #HappyInternationalDayforInterventionalCardiology to all interventional cardiologists! Your dedication to saving lives and improving patient outcomes inspires us to continue innovating. #Biocalculus

At the Focal Point, Caixia Fan and colleagues partake in "Noninvasive endoscopic therapy of gourd-shaped appendix stenosis: an easier and effective path to follow." Read the article at https://lnkd.in/gJpGvpR3.